Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Hexima Limited
  6. News
  7. Summary
    HXL   AU0000111932

HEXIMA LIMITED

(HXL)
  Report
Delayed Quote. Delayed Australian Stock Exchange - 01/18 09:29:27 pm
0.395 AUD   +1.94%
01/03Hexima Appoints Commercial Chief
MT
01/03Phillip Rose Appoints Phillip Rose as Chief Commercial Officer
CI
2021HEXIMA : Notification regarding unquoted securities - HXL
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Hexima : R&D Webinar on TodayOpens in a new Window

03/24/2021 | 05:59pm EST

ASX Announcement

25 March 2021

R&D Webinar on Today at 11 am

MELBOURNE, AUSTRALIA (25 March 2021): Hexima Limited (ASX:HXL) a clinical stage biotechnology company developing HXP124, a new prescription treatment for onychomycosis, is holding an R&D Webinar today at 11 am. This webinar is an opportunity to hear the fascinating story of how the scientific data Hexima has generated on HXP124 in the laboratory is now playing out in the real world as it conducts advanced clinical trials on HXP124 as a potential new topical treatment for onychomycosis. A copy of the presentation is appended to this announcement.

Attendees can register to attend the webinar using the link below.

https://zoom.us/webinar/register/WN_MN-oT3ELRle_oOLtdBcuqw

About Hexima

Hexima (ASX:HXL) is an anti-infectives focused, clinical stage, biotechnology company engaged in the research and development of plant-derived defensin peptides for applications as human therapeutics. Its lead product candidate, HXP124 applied in a topical formulation, is a potential new prescription treatment for toenail fungal infections (or onychomycosis). Hexima is currently conducting an Australian phase IIb clinical trial of HXP124 in onychomycosis. Hexima holds granted, long-life patents protecting HXP124 and other anti-fungal molecules in major markets globally. For additional information about Hexima please visit www.hexima.com.au.

This announcement is authorised for release to ASX by Michael Aldridge, CEO and Managing Director.

Enquiries:

Dr Nicole van der Weerden Chief Operating Officer n.vanderweerden@hexima.com.au

Join our email database to receive company announcements:

Info@hexima.com.auwww.hexima.com.au

25 March 2021 11:00 am

Disclaimer

Summary information

This presentation has been prepared by Hexima Ltd and its subsidiaries (collectively "Hexima"). The information in this presentation is of general background in summary form which is current as of March 2021 and does not purport to be complete. It does not contain all information relevant or necessary for an investment decision or that would be required to be included in a prospectus under the Corporations Act 2001 (Cth) (Corporations Act). The information in this presentation is subject to change without notice. No representation or warranty, express or implied, is made by Hexima or any of its advisers as to the accuracy, adequacy or reliability of any information contained in this presentation.

Not an offer

This presentation is not a prospectus or any other offering document under Australian law or any other law (and will not be lodged with ASIC). This presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The distribution of this presentation outside Australia may be restricted by law. Any recipient of this presentation who is outside Australia must seek advice on and observe any such restrictions. This presentation may not be reproduced or published, in whole or in part, for any purpose without the prior written permission of Hexima. An investment in securities is subject to known and unknown risks, some of which are beyond the control of Hexima, including possible loss of income and principal invested. Hexima does not guarantee any particular rate of return or the performance of Hexima, nor does it guarantee any particular tax treatment. Investors should have regard to potential risks outlined in this presentation when making their investment decision.

Not financial or product advice

This presentation is for information purposes only and is not a prospectus, product disclosure statement or other offer document under Australian law or the law of any other jurisdiction. This document is not a financial product or investment advice, or a recommendation to acquire securities in Hexima, nor is it legal or tax advice. It has been prepared without taking into account the objectives, financial situation or needs of individuals. You are solely responsible for seeking independent and professional advice in relation to the information contained in this presentation and any action taken on the basis of that information. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial and tax situation and needs and seek legal and taxation advice appropriate to their jurisdiction. No reliance may be placed for any purpose whatsoever on the information included in this presentation or on its accuracy or completeness.

Financial data

All dollar values are in Australian dollars (A$) unless stated otherwise.

Performance

Past performance information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of future performance. The presentation includes forward-looking statements regarding future events and the future financial performance of Hexima. Forward looking words such as "expect", "should", "could", "may", "predict", "plan", "will", "believe", "forecast", "estimate", "target" or other similar expressions are intended to identify forward-looking statements. Any forward looking statements included in this document involve subjective judgment and analysis and are subject to significant uncertainties, risks and contingencies, many of which are outside the control of, and are unknown to, Hexima and its officers, employees, agents or associates. In particular, factors such as outcomes of clinical trials and regulatory decisions and processes may affect the future operating and financial performance of Hexima. This may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. The information also assumes the success of Hexima's business strategies. The success of the strategies is subject to uncertainties and contingencies beyond control, and no assurance can be given that the anticipated benefits from the strategies will be realised in the periods for which forecasts have been prepared or otherwise. Given these uncertainties, you are cautioned to not place undue reliance on any such forward looking statements. Hexima is providing this information as of the date of this presentation and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

Disclaimer

Except as required by law, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness, reliability or correctness of the Information, opinions and conclusions, or as to the reasonableness of any assumption contained in this presentation. By receiving this presentation and to the extent permitted by law, you release Hexima and its officers, employees, agents and associates from any liability (including, without limitation, in respect of direct, indirect or consequential loss or damage or loss or damage arising by negligence) arising as a result of the reliance by you or any other person on anything contained in or omitted from this presentation. To the maximum extent permitted by law, Hexima and its respective advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents exclude and disclaim all liability, including without limitation for negligence or for any expenses, losses, damages or costs incurred by you as a result of the information in the presentation being inaccurate or incomplete in any way for any reason, whether by negligence or otherwise. To the maximum extent permitted by law, Hexima and its advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this presentation.

NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES

2

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Hexima Limited published this content on 25 March 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 March 2021 22:58:01 UTC.


ę Publicnow 2021
All news about HEXIMA LIMITED
01/03Hexima Appoints Commercial Chief
MT
01/03Phillip Rose Appoints Phillip Rose as Chief Commercial Officer
CI
2021HEXIMA : Notification regarding unquoted securities - HXL
PU
2021HEXIMA : Notification regarding unquoted securities - HXL
PU
2021Hexima Names New Chief Development Officer
MT
2021HEXIMA : CEO's Presentation
PU
2021Hexima Limited Announces Cessation of Marilyn Anderson as Executive Director
CI
2021Hexima Limited Announces Appointment of Shari Lipner as Member of its Scientific Adviso..
CI
2021Hexima Limited Announces Appointment of Nancy Sacco as Chief Development Officer
CI
2021Hexima Completes Oversubscribed Share Purchase Plan
MT
More news
Financials
Sales 2022 - - -
Net income 2022 -9,30 M -6,72 M -6,72 M
Net cash 2022 41,5 M 30,0 M 30,0 M
P/E ratio 2022 -6,77x
Yield 2022 -
Capitalization 65,3 M 47,4 M 47,2 M
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees -
Free-Float 69,6%
Chart HEXIMA LIMITED
Duration : Period :
Hexima Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 0,40 AUD
Average target price 0,75 AUD
Spread / Average Target 89,9%
EPS Revisions
Managers and Directors
Michael Douglas Arthur Aldridge CEO, Non-Independent Non-Executive Director & MD
Jonathan West Non-Executive Chairman
Marilyn Ann Anderson Chief Scientific Officer
Yolanda Gaspar Head-Clinical Operations
Nicole Louise van der Weerden Director
Sector and Competitors
1st jan.Capi. (M$)
HEXIMA LIMITED-4.82%47
MODERNA, INC.-31.46%70 577
LONZA GROUP AG-14.10%53 088
IQVIA HOLDINGS INC.-14.84%45 903
SEAGEN INC.-14.26%24 238
ICON PUBLIC LIMITED COMPANY-17.00%20 923